P152. The effect of frailty on outcome after traumatic spinal cord injury
Daniel Banaszek, MD, FRCSC1; Tom Inglis, MbChB2; Tamir Ailon, MD, MPH3; Raphaële Charest-Morin, MD4; Nicolas Dea, MD, MSc, FRCSC5; Charles G. Fisher, MD, FRCSC, MHS1; Brian K. Kwon, MD, PhD, FRCSC5; Scott J. Paquette, MD1; John Street, MD, PhD5
1Vancouver General Hospital, Vancouver, BC, Canada; 2Whangarei Hospital, Whangarei, New Zealand; 3Vancouver Spine Surgery Institute, Vancouver, BC, Canada; 4Quebec, QC, Canada; 5Blusson Spinal Cord Center, Vancouver, BC, Canada
FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
P153. Sarcopenia, independent of age, predicts mortality and acute care adverse events in patients with traumatic spinal cord injury
Daniel Banaszek, MD, FRCSC1; Tom Inglis, MbChB2; Tamir Ailon, MD, MPH3; Raphaële Charest-Morin, MD4; Nicolas Dea, MD, MSc, FRCSC5; Charles G. Fisher, MD, FRCSC, MHS1; Brian K. Kwon, MD, PhD, FRCSC5; Scott J. Paquette, MD1; John Street, MD, PhD5
1Vancouver General Hospital, Vancouver, BC, Canada; 2Whangarei Hospital, Whangarei, New Zealand; 3Vancouver Spine Surgery Institute, Vancouver, BC, Canada; 4Quebec, QC, Canada; 5Blusson Spinal Cord Center, Vancouver, BC, Canada
FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.